AT 193
Alternative Names: AT-193Latest Information Update: 28 Jan 2025
At a glance
- Originator Azora Therapeutics
- Class Anti-inflammatories; Indoles; Skin disorder therapies; Small molecules
- Mechanism of Action Aryl hydrocarbon hydroxylase inhibitors; Aryl hydrocarbon receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Atopic dermatitis; Hidradenitis suppurativa
- No development reported Psoriasis
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for phase-I development in Psoriasis in Australia (Topical)
- 28 Oct 2024 No recent reports of development identified for phase-I development in Hidradenitis suppurativa(In the elderly, In adults) in Australia (Topical)
- 15 Mar 2024 Azora Therapeutics completes a phase I clinical trials in Hidradenitis suppurativa (In adults, In the elderly) in Australia (Topical) (NCT04989517)